Skip to the page

Data / Drug companies / Cosette Pharmaceuticals, Inc.

Cosette Pharmaceuticals, Inc.: 95 products in the FDA NDC directory, labeler code 0713

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Cosette Pharmaceuticals, Inc. (labeler code 0713) lists 95 products in the FDA National Drug Code Directory, covering 47 finished drugs by generic name. By type: 90 prescription drugs, 5 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 1, 2026.

The request: Watch Cosette Pharmaceuticals, Inc. (FDA labeler code 0713): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0713
Products in commercial distribution
95
Packages
148
Finished drugs by generic name
47
Prescription products
90
Over the counter products
5
Controlled substance products
Schedule IV 4, Schedule V 1
Flagged as original packager
95 of 95 products that carry the flag
Started marketing in the last 12 months
6
Earliest marketing start
March 24, 1983
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)5962.1%
New drug applications (NDA)3132.6%
Over the counter monograph drugs33.2%
Other unapproved drugs22.1%

Products by type

TypeProductsShare
Prescription drugs9094.7%
Over the counter drugs55.3%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet, film coated2324.2%
Cream2021.1%
Ointment1515.8%
Suppository88.4%
Gel66.3%
Solution44.2%
Tablet, coated44.2%
Suspension33.2%
Capsule22.1%
Lotion22.1%
Injection22.1%
Shampoo, suspension11.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Benicar HCT0713-0945Tablet, film coatedNew drug applications (NDA)April 1, 2026
Benicar HCT0713-0943Tablet, film coatedNew drug applications (NDA)April 1, 2026
Benicar HCT0713-0944Tablet, film coatedNew drug applications (NDA)March 3, 2026
Promethazine Hydrochloride and Codeine Phosphate0713-0823SolutionGeneric drugs (ANDA)December 19, 2025
Ciprofloxacin hydrochloride and hydrocortisone0713-0851Suspension/ dropsGeneric drugs (ANDA)December 4, 2025
Vyleesi0713-0897InjectionNew drug applications (NDA)November 12, 2025
Promethazine Hydrochloride and Dextromethorphan Hydrobromide0713-0780SolutionGeneric drugs (ANDA)September 19, 2025
Benicar0713-0942Tablet, film coatedNew drug applications (NDA)August 1, 2025
Benicar0713-0941Tablet, film coatedNew drug applications (NDA)August 1, 2025
Benicar0713-0940Tablet, film coatedNew drug applications (NDA)August 1, 2025
Tazarotene0713-0765CreamGeneric drugs (ANDA)March 10, 2025
Ambien CR0713-5521Tablet, coatedNew drug applications (NDA)February 7, 2025
Ambien CR0713-5501Tablet, coatedNew drug applications (NDA)February 7, 2025
Ambien0713-5421Tablet, film coatedNew drug applications (NDA)February 7, 2025
Ambien0713-5401Tablet, film coatedNew drug applications (NDA)February 7, 2025
Ketoconazole0713-0592Shampoo, suspensionGeneric drugs (ANDA)February 7, 2025
MICONAZOLE 3 COMBINATION PACK (miconazole nitrate) kit0713-0593KitGeneric drugs (ANDA)January 3, 2025
Sucralfate0713-0791SuspensionGeneric drugs (ANDA)December 19, 2024
Calcipotriene and betamethasone dipropionate0713-0848SuspensionGeneric drugs (ANDA)August 2, 2024
Nitroglycerin0713-0564OintmentGeneric drugs (ANDA)February 23, 2024
Hydrocortisone and acetic acid0713-0849SolutionGeneric drugs (ANDA)February 1, 2024
Docosanol0713-0353CreamGeneric drugs (ANDA)January 4, 2024
Metronidazole0713-0575GelGeneric drugs (ANDA)July 12, 2023
Dapsone0713-0886GelGeneric drugs (ANDA)May 8, 2023
Metronidazole0713-0574GelGeneric drugs (ANDA)February 1, 2023

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.